News Medical

How new approach methodologies and regulation are shaping safer, more predictive therapeutics outcomes

As regulatory authorities accelerate the use of New Approach Methodologies (NAMs), the drug discovery landscape is changing dramatically. This webinar explores how NAMs, immunology-driven ...
GEN

The Newest New Approach Methodologies

Although new approach methodologies (NAMs) are not that new, they remain a crucial and evolving aspect of the development and production of biopharmaceuticals. “NAMs have been around for 20 ...
TMCnet

Draper and Partners Awarded ARPA-H Funding to Develop New In Silico Models of Human Physiology for Drug Development

Draper recently received an up to $26.7 million other transaction award (OTA) from the Advanced Research Projects Agency for Health (ARPA-H). The award supports the agency's Computational ADME-Tox and ...
Medscape

FDA Changes Drug Trial Guidance: Experts Take Sides

The FDA has opened the door to the use of Bayesian statistical methods in clinical trials. The worry: Introducing ...
Benzinga.com

DiNABIOS Applauds Historic U.S. Senate Passage of FDA Modernization Act 3.0, Advancing Human‑Relevant New Approach Methodologies (NAMs)

DiNABIOS Applauds Historic U.S. Senate Passage of FDA Modernization Act 3.0, Advancing Human‑Relevant New Approach Methodologies (NAMs) ZURICH/SCHLIEREN, Switzerland, December 24, 2025 – ...
Medical Xpress

New paper urges caution as FDA plans to phase out animal testing in drug development

Replacing animal testing with alternate methodologies in preclinical drug trials holds potential for the development of cheaper, safer pharmaceuticals as well as alleviating animal suffering. But ...
BioTechniques

Infographic: Integrating new approach methodologies into your therapeutics development research

New approach methodologies (NAMs) – such as organoids, spheroids and microfluidic chip systems – aim to streamline early-stage drug discovery and revolutionize preclinical testing by ...
TMCnet

IQVIA Signs Agreement to Acquire Drug Discovery Assets from Charles River Laboratories, Expanding End-to-End Drug Discovery Capabilities

IQVIA Holdings Inc. ("IQVIA") (NYSE: IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has ...